2000 Central Avenue
Suite 100
Boulder, CO 80301
United States
720 505 4755
https://ir.frtx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 4
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Albert Nicholas Marchio II | CEO, CFO, Secretary & Chairman | 251.83k | N/D | 1952 |
Aron Aizenstat M.B.A., P.M.P. | Vice President of Corporate Development & Operations | N/D | N/D | N/D |
Mr. Aaron Fox-Collis CPA | VP of Finance & Chief Accounting Officer | N/D | N/D | N/D |
Ms. Sue Fattor | Head of Human Resource | N/D | N/D | N/D |
Dr. James S. McElvain Ph.D. | Interim Head of CMC Development | N/D | N/D | N/D |
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
La calificación ISS Governance QuickScore de Fresh Tracks Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.